---
title: "Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295445714.md"
description: "On August 10, 2026, Erasca, Inc. (Nasdaq: ERAS), a company specializing in precision oncology, revealed the appointment of Charles S. Fuchs, M.D., M.P.H., as the president of research and development. Focusing on developing therapies for patients with RAS/MAPK pathway-driven cancers, Erasca's Board of Directors sanctioned the issuance of inducement awards to Dr. Fuchs."
datetime: "2026-08-10T20:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295445714.md)
  - [en](https://longbridge.com/en/news/295445714.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295445714.md)
---

# Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On August 10, 2026, Erasca, Inc. (Nasdaq: ERAS), a company specializing in precision oncology, revealed the appointment of Charles S. Fuchs, M.D., M.P.H., as the president of research and development. Focusing on developing therapies for patients with RAS/MAPK pathway-driven cancers, Erasca's Board of Directors sanctioned the issuance of inducement awards to Dr. Fuchs.

### Related Stocks

- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)

## Related News & Research

- [Erasca rilis presentasi korporat soal pengembangan terapi kanker berbasis jalur RAS/MAPK](https://longbridge.com/en/news/295578619.md)
- [Erasca grants new R&D chief Charles Fuchs options for 1,278,520 shares under inducement plan](https://longbridge.com/en/news/295443047.md)
- [Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | ANIX Stock News](https://longbridge.com/en/news/296231345.md)
- [Erasca files Form 3 for President, R&D Charles S. Fuchs](https://longbridge.com/en/news/295705135.md)
- [Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy](https://longbridge.com/en/news/296250397.md)